Peripheral blood mitochondrial DNA copy number as a novel potential biomarker for diabetic nephropathy in type 2 diabetes patients

被引:44
|
作者
Al-Kafaji, Ghada [1 ,2 ]
Aljadaan, Abdulah [1 ,2 ]
Kamal, Amer [3 ]
Bakhiet, Moiz [1 ,2 ]
机构
[1] Arabian Gulf Univ, Coll Med & Med Sci, Dept Mol Med, Salmaniya Ave,Bldg 293,Rd 2904,Block 329, Manama 329, Bahrain
[2] Arabian Gulf Univ, Coll Med & Med Sci, Al Jawhara Ctr Mol Med Genet & Inherited Disorder, Salmaniya Ave,Bldg 293,Rd 2904,Block 329, Manama 329, Bahrain
[3] Arabian Gulf Univ, Coll Med & Med Sci, Dept Physiol, Manama 329, Bahrain
关键词
diabetic nephropathy; mitochondrial DNA copy number; peripheral blood; biomarker; GLOMERULAR-FILTRATION RATE; RENAL MESANGIAL CELLS; OXIDATIVE STRESS; HIGH-GLUCOSE; MOLECULAR-MECHANISMS; KIDNEY-DISEASE; MELLITUS; MICROALBUMINURIA; COMPLICATIONS; PREVALENCE;
D O I
10.3892/etm.2018.6319
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The mitochondrial DNA copy number (mtDNA-CN) is a surrogate measure of mitochondria' function and altered mtDNA-CN reflects the oxidant-induced cell damage. A previous study by our group demonstrated that a reduction in the renal mtDNA-CN is implicated in the pathogenesis of diabetic nephropathy (DN), a leading cause of end-stage renal disease in diabetic patients. In the present study, it was investigated whether the mtDNA-CN in the peripheral blood may be utilized as a biomarker for DN in type 2 diabetes (T2D) patients. The study included 50 non-diabetic and 100 diabetic subjects. The diabetic subjects were sub-divided based on their albumin-to-creatinine ratio (ACR) into T2D patients with normoalbuminuria (n=50), DN patients with microalbuminuria (n=29) and DN patients with macroalbuminuria (n=21). The mtDNA-CN was measured in the peripheral blood by real-time polymerase chain reaction analysis. Patients with DN had a lower mtDNA-CN than patients with T2D and healthy controls (P<0.05). A sub-group analysis with stratification by the ACR indicated that a decreased mtDNA-CN was associated with the severity and the presence of DN, as it was lower in DN patients with macroalbuminuria than in DN patients with microalbuminuria and T2D patients with normoalbuminuria (P<0.01). The area under the receiver operating characteristic curve (AUC) for mtDNA-CN was 0.916 (sensitivity, 86% and specificity, 74%) and 0.961 (sensitivity, 96% and specificity, 88%) for differentiating DN patients from T2D patients without DN and from healthy controls, respectively. Furthermore, the AUC of mtDNA-CN for differentiating DN patients with microalbuminuria from those with macroalbuminuria was 0.895 (sensitivity, 83% and specificity, 85%). Multivariate analysis revealed that the mtDNA-CN was significantly associated with the occurrence and progression of DN, even after adjustment liar age, mean blood pressure, glycated haemoglobin Ale and total cholesterol (P<0.05). In patients with DN, a decreased mtDNA-CN was negatively correlated with albuminuria and conventional risk factors for DN, and was positively correlated with the estimated glomerular filtration rate. The present results therefore suggest the utilization of circulating mtDNA-CN as a novel biomarker for the early diagnosis of DN and indicate the significance of decreased mtDNA-CN as another independent risk factor for DN.
引用
收藏
页码:1483 / 1492
页数:10
相关论文
共 50 条
  • [21] Mitochondrial DNA copy number variation - A potential biomarker for early onset preeclampsia
    Pandey, Deeksha
    Yevale, Aarti
    Naha, Ritam
    Kuthethur, Raviprasad
    Chakrabarty, Sanjiban
    Satyamoorthy, Kapaettu
    PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH, 2021, 23 : 1 - 4
  • [22] Mitochondrial DNA copy number in adults with and without Type 1 diabetes
    Jenkins, Alicia J.
    Carroll, Luke M.
    Huang, Michael L. H.
    Wen-Loh, Yik
    Mangani, Abubakar
    O'Neal, David N.
    Januszewski, Andrzej S.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 203
  • [23] The effect of exercise on the mitochondrial DNA copy number in peripheral blood in healthy women
    Lim, S
    Kim, SK
    Kim, WB
    Park, DJ
    Park, KS
    Kim, SY
    Cho, BY
    Lee, HK
    DIABETES MELLITUS: RECENT ADVANCES FOR THE 21ST CENTURY, 2000, 1209 : 461 - 464
  • [24] Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes
    Cho, Noo Ree
    Yu, Yeuni
    Oh, Chang-Kyu
    Ko, Dai Sik
    Myung, Kyungjae
    Lee, Yoonsung
    Na, Hee Sam
    Kim, Yun Hak
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2021, 12
  • [25] Reduced Peripheral Blood Mitochondrial DNA Copy Number as Identification Biomarker of Suspected Arsenic-Induced Liver Damage
    Wang, Qi
    Ma, Lu
    Sun, Baofei
    Zhang, Aihua
    BIOLOGICAL TRACE ELEMENT RESEARCH, 2023, 201 (11) : 5083 - 5097
  • [26] Reduced Peripheral Blood Mitochondrial DNA Copy Number as Identification Biomarker of Suspected Arsenic-Induced Liver Damage
    Qi Wang
    Lu Ma
    Baofei Sun
    Aihua Zhang
    Biological Trace Element Research, 2023, 201 : 5083 - 5097
  • [27] Serum LncRNA PANDAR may Act as a Novel Serum Biomarker of Diabetic Nephropathy in Patients with Type 2 Diabetes
    Zhao, Chun
    Hu, Jie
    Wang, Zun
    Cao, Zhen-Yu
    Wang, Lei
    CLINICAL LABORATORY, 2020, 66 (06) : 1067 - 1072
  • [28] Usefulness of circulating mitochondrial DNA copy number as a prognostic biomarker in metastatic patients
    Moreau, M.
    Nelo, V.
    Pata-Merci, N.
    Stourm, A.
    Saulnier, P.
    Rouleau, E.
    Lacroix, L.
    Vasseur, D.
    ANNALS OF ONCOLOGY, 2022, 33 (08) : S1405 - S1405
  • [29] Leukocyte mitochondrial DNA copy number is a potential non-invasive biomarker for psoriasis
    Alwehaidah, Materah Salem
    AlFadhli, Suad
    Al-Kafaji, Ghada
    PLOS ONE, 2022, 17 (06):
  • [30] Mitochondrial DNA Copy Number Is a Potential Biomarker for Treatment Choice Between Metformin and Acarbose
    Wang, Jing
    Liang, Hua
    Wang, You
    Zheng, Xueying
    Chen, Fei
    Shao, Jian
    Geng, Zhaoxu
    Zheng, Li
    Yang, Wenying
    Weng, Jianping
    Xu, Tao
    Zhou, Kaixin
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (06) : 1268 - 1273